Un(b)locking therapeutic options: Potential for calcium channel blockers in heart failure with non‐reduced left ventricular ejection fraction.

This article discusses the use of calcium channel blockers (CCBs) in the treatment of heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). The article highlights that while certain therapies have been approved for heart failure with reduced ejection fraction (HFrEF) and have shown benefits for HFmrEF and HFpEF, the evidence base for beta-blockade in HFpEF is poor. The article presents a study that analyzes the association of CCBs on outcomes in patients with HFmrEF and HFpEF, finding that CCB use was associated with no difference in cardiovascular death or heart failure hospitalization. However, CCB use was associated with a lower risk of death due to pump failure and a higher risk of non-fatal stroke. The article suggests that dihydropyridine CCBs could be considered for managing comorbidities in patients with HFmrEF and HFpEF without increasing the risk of heart failure-related outcomes. The study has limitations, and further research is needed to fully understand the effects of CCBs in these patient populations. Overall, the article provides valuable insights into the use of medications in heart failure treatment and calls for a reconsideration of traditional concepts regarding indicated and contraindicated therapies. [Extracted from the article]